Intensity Therapeutics, Inc. (INTS) company profile

Intensity Therapeutics, Inc. is a clinical-stage biotechnology company developing localized intratumoral cancer therapies designed to stimulate systemic anti-cancer immune activation. Utilizing its proprietary DfuseRx discovery platform, the company creates formulations combining generic anti-cancer cytotoxic agents, such as cisplatin and vinblastine sulfate, with amphiphilic molecules to facilitate drug penetration and dispersion throughout dense tumor microenvironments. Its core product candidate, INT230-6, targets various solid tumors, including soft tissue sarcoma and early-stage or triple-negative breast cancer, serving cancer patients with major unmet medical needs.

The company conducts clinical trials across multiple countries, including the United States, Canada, Australia, France, Germany, Italy, Poland, and Switzerland. Up to 60 specialized sarcoma hospitals and research centers participate internationally in its studies. The provided text does not mention the location of the company's corporate headquarters.

Summary of the business section of Intensity Therapeutics's latest annual report, written by StockData.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“Per Share Total Initial public offering price $ 5.00 $ 19,500,000 Underwriting discounts and commissions (1) $ 0.35 $ 1,365,000 Proceeds, before expenses, to us $ 4.65 $ 18,135,000 ____________ (1) See “Underwriting” beginning on page 132 of this prospectus for additional information regarding the compensation and”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of March 1, 2026, we had sixteen employees and contractors, including one with an M.D.”